A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
NCT ID: NCT06441630
Last Updated: 2025-02-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
251 participants
INTERVENTIONAL
2024-07-31
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102
NCT04600284
S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension
NCT03226340
Essential Hypertension
NCT01264692
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
NCT02620163
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed Conditions
NCT06744062
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Co-administration of AD-227A and AD-227B
AD-227A + AD-227B + Placebo of AD-227C
AD-227A
Per Oral, 1 Tablet, Once a day for 8 weeks
AD-227B
Per Oral, 1 Tablet, Once a day for 8 weeks
Placebo of AD-227C
Per Oral, 1 Tablet, Once a day for 8 weeks
AD-227A
AD-227A + Placebo of AD-227B + Placebo of AD-227C
AD-227A
Per Oral, 1 Tablet, Once a day for 8 weeks
Placebo of AD-227B
Per Oral, 1 Tablet, Once a day for 8 weeks
Placebo of AD-227C
Per Oral, 1 Tablet, Once a day for 8 weeks
Co-administration of AD-227A and AD-227C
AD-227A + Placebo of AD-227B + AD-227C
AD-227A
Per Oral, 1 Tablet, Once a day for 8 weeks
AD-227C
Per Oral, 1 Tablet, Once a day for 8 weeks
Placebo of AD-227B
Per Oral, 1 Tablet, Once a day for 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AD-227A
Per Oral, 1 Tablet, Once a day for 8 weeks
AD-227B
Per Oral, 1 Tablet, Once a day for 8 weeks
AD-227C
Per Oral, 1 Tablet, Once a day for 8 weeks
Placebo of AD-227B
Per Oral, 1 Tablet, Once a day for 8 weeks
Placebo of AD-227C
Per Oral, 1 Tablet, Once a day for 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with Essential Hypertension
* Other inclusions applied
Exclusion Criteria
* Other exclusions applied
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Addpharma Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chong-Jin Kim
Role: PRINCIPAL_INVESTIGATOR
Gangnam CHA Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gangnam CHA Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AD-227P3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.